cryptosporidium parvum oocysts
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 17, 2022 (NCT05036668)
Timeline
Indications
Studied for
Mechanism of action
- Cryptosporidium parvumImmunity, active
Cryptosporidium parvum immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07249463 | Phase 2 | Nov 25, 2025 | Novartis |
| NCT05036668 | Phase 1 | Mar 17, 2022 | Novartis, Pharmaron |
Showing 2 of 2 trials
Page 1 / 1